-
ASH China Voice | Prof. Xiaoxia Hu / Dr. Zilu Zhang: IPSS-M and Conditioning Intensity in Transplant Decision-Making for MDS
Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative option for patients with myelodysplastic syndromes (MDS). However, clinical decision-making in the transplant setting remains challenging. Two critical and unresolved issues…
-
News Bulletin · CML Highlights | Prof. Qian Jiang: Global Frontiers in CML and the Chinese Perspective
The 2025 Annual Meeting of the American Society of Hematology (ASH) was held in Orlando from December 6 to 9. As one of the world’s premier events in hematology, the…
-
ASH China Voice | Prof. Yi Luo & Lizhen Liu: Preemptive Ven+Aza Therapy Offers a New Strategy to Prevent Post-Transplant Relapse in AML/MDS
CAR-T cell therapy has achieved transformative success in lymphoid malignancies, yet its application in acute myeloid leukemia (AML) remains highly challenging. Against this backdrop, a sequential strategy integrating CD7-targeted CAR-T…
-
ASH China Voice | Prof. Yi Luo & Lizhen Liu: Preemptive Ven+Aza Opens a New Strategy to Prevent Post-Transplant Relapse in AML/MDS
At a recent Annual Meeting of the American Society of Hematology (ASH), a prospective study conducted by Prof. Yi Luo’s team at The First Affiliated Hospital, Zhejiang University School of…
-
ASH China Voice | Prof. Rong Fu’s Team: Advances and Precision Treatment Strategies in AA, PNH, and MDS
December 6–9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. As the world’s largest and most influential hematology conference, ASH annually…
-
On-site from ESMO Asia | Dr. Yongbing Cheng (Team of Professor Guo Hongqian):
“Fewer Cores Without Losing Accuracy” — A New Strategy of MRI-Targeted Biopsy Plus Ipsilateral Systematic Biopsy of the Index Lesion in Prostate Cancer Editor’s Note: Prostate cancer is one of…
-
Professor Wasilijiang·Wahafu: Targeted Therapy Plus Immunotherapy Redefines Advanced Urothelial Carcinoma Care with Multidisciplinary Support
Editor’s Note: Advanced urothelial carcinoma is a highly aggressive malignancy associated with poor prognosis, posing a serious threat to patient survival and quality of life. In recent years, continuous breakthroughs…
-
Professor Kohei Shitara: Advancing Immunotherapy in Gastrointestinal Cancers—Cancer Vaccines, T-Cell Engagers, and Other Emerging Strategies May Lead the Next Wave
Immunotherapy has fundamentally reshaped the treatment landscape of gastrointestinal (GI) cancers. However, now that PD-1/PD-L1 inhibitors have been firmly established as standards of care, the key challenge facing clinical research is how to further overcome the current efficacy plateau. This has driven research into a “deep-water zone,” where novel strategies—such as next-generation TIGIT inhibitors, cancer…
Connecting Medical Expertise through Media